The estimated Net Worth of David J Moss is at least 8.68 百万$ dollars as of 17 March 2023. Mr Moss owns over 2,500 units of INmune Bio stock worth over 7,788,441$ and over the last 5 years he sold INMB stock worth over 586,680$. In addition, he makes 300,000$ as CFO、 Treasurer & Sec. at INmune Bio.
Sign up
Mr A INMB stock SEC Form 4 insiders trading
Mr has made over 9 trades of the INmune Bio stock since 2019, according to the Form 4 filled with the SEC. Most recently he bought 2,500 units of INMB stock worth 16,075$ on 17 March 2023.
The largest trade he's ever made was exercising 25,000 units of INmune Bio stock on 16 July 2021 worth over 97,750$. On average, Mr trades about 5,029 units every 86 days since 2019. As of 17 March 2023 he still owns at least 1,250,151 units of INmune Bio stock.
You can see the complete history of Mr Moss stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Mr. David J. Moss M.B.A. biography
David J. Moss M.B.A. is the CFO, Treasurer & Sec. at INmune Bio.
What is the salary of Mr A?
As the CFO、 Treasurer & Sec. of INmune Bio, the total compensation of Mr A at INmune Bio is 300,000$. There are 1 executives at INmune Bio getting paid more, with Dr. Raymond Joseph Tesi M.D. having the highest compensation of 455,000$.
How old is Mr A?
Mr A is 51, he's been the CFO、 Treasurer & Sec. of INmune Bio since . There are 4 older and no younger executives at INmune Bio. The oldest executive at INmune Bio, Inc. is Dr. Raymond Joseph Tesi, 65, who is the Co-Founder, Pres, CEO, Chief Medical Officer & Chairman.
What's Mr A's mailing address?
David's mailing address filed with the SEC is C/O INMUNE BIO INC., 225 NE MIZNER BLVD., SUITE 640, BOCA RATON,, FL, 33432.
Insiders trading at INmune Bio
Over the last 5 years, insiders at INmune Bio have traded over 5,236,202$ worth of INmune Bio stock and bought 82,618 units worth 534,813$ . The most active insiders traders include Linda F Powers、Edgardo Jr Baracchini、Inc Xencor. On average, INmune Bio executives and independent directors trade stock every 51 days with the average trade being worth of 117,087$. The most recent stock trade was executed by Scott Juda on 25 June 2024, trading 5,000 units of INMB stock currently worth 36,350$.
What does INmune Bio do?
INmune Bio, Inc., a clinical-stage immunotherapy company, focuses on developing drugs to reprogram the patient's innate immune system to treat disease. The company develops and commercializes product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. Its development programs include INKmune, which focuses on treating women with relapse refractory ovarian carcinoma and patients with high-risk myelodysplastic syndrome; INB03, an immunotherapy that treats patients with hematologic malignancies and solid tumors; and XPro1595 for the treatment of Alzheimer's disease. The company has license agreements with Xencor, Inc.; Immune Ventures, LLC; University of Pittsburg; and University College London. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.
What does INmune Bio's logo look like?
Complete history of Mr Moss stock trades at INmune Bio
INmune Bio executives and stock owners
INmune Bio executives and other stock owners filed with the SEC include:
-
Dr. Raymond Joseph Tesi M.D.,
Co-Founder, Pres, CEO, Chief Medical Officer & Chairman -
David J. Moss M.B.A.,
CFO, Treasurer & Sec. -
Dr. Raymond Joseph Tesi,
Co-Founder, Pres, CEO, Chief Medical Officer & Chairman -
Dr. Mark William Lowdell BSc, FRCPath, MICR, MSc, Ph.D.,
Chief Scientific Officer & Chief Manufacturing Officer -
Dr. Mark William Lowdell BSc, MSc, Ph.D., FRCPath, MICR,
Chief Scientific Officer & Chief Manufacturing Officer -
Dr. Christopher J. Barnum,
Director of Neuroscience -
Joshua S. Schoonover Esq.,
Assoc. Gen. Counsel -
Scott Juda,
Director -
Inc Xencor,
-
Timothy J Schroeder,
Director -
Edgardo Jr Baracchini,
Director -
James Kelly Ganjei,
Director -
Linda F Powers,
-
Marcia Allen,
Director -
Raymond Joseph Tesi,
President and CEO -
Mark William Lowdell,
Chief Scientific Officer -
David J Moss,
Chief Financial Officer